{
    "organizations": [],
    "uuid": "e79ebd101b62ad90e5ca94a860a011d13e07ef36",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lipocine-says-fdas-brudac-voted-6/brief-lipocine-says-fdas-brudac-voted-6-in-favor-13-against-benefit-risk-profile-of-tlando-idUSFWN1P50QW",
    "ord_in_thread": 0,
    "title": "BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 10, 2018 / 9:34 PM / Updated 9 minutes ago BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando Reuters Staff 1 Min Read \nJan 10 (Reuters) - Lipocine Inc: \n* LIPOCINE - FDA‘S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO‘S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO \n* LIPOCINE INC SAYS ‍FDA DECISION ON TLANDO NDA IS ANTICIPATED BY ASSIGNED PDUFA GOAL DATE OF MAY 8, 2018 - SEC FILING ​ \n* LIPOCINE INC - CONTINUE TO BELIEVE EFFICACY AND SAFETY RESULTS FROM CLINICAL STUDIES WITH TLANDO CONSISTENT WITH OTHER FDA APPROVED TRT PRODUCTS Source text: ( bit.ly/2mnVzkJ ) Further company coverage:",
    "published": "2018-01-10T23:33:00.000+02:00",
    "crawled": "2018-01-10T23:50:33.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "fda",
        "brudac",
        "voted",
        "favor",
        "profile",
        "tlando",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "lipocine",
        "inc",
        "lipocine",
        "fda",
        "brudac",
        "voted",
        "favor",
        "profile",
        "co",
        "oral",
        "testosterone",
        "product",
        "candidate",
        "trt",
        "adult",
        "male",
        "tlando",
        "lipocine",
        "inc",
        "say",
        "decision",
        "tlando",
        "nda",
        "anticipated",
        "assigned",
        "pdufa",
        "goal",
        "date",
        "may",
        "sec",
        "filing",
        "lipocine",
        "inc",
        "continue",
        "believe",
        "efficacy",
        "safety",
        "result",
        "clinical",
        "study",
        "tlando",
        "consistent",
        "fda",
        "approved",
        "trt",
        "product",
        "source",
        "text",
        "company",
        "coverage"
    ]
}